TGA approves first-of-its-kind GLP-1 weight loss pill Foundayo for Australian use

Sayan
By Sayan
4 Min Read
Disclosure: This website may contain affiliate links, which means I may earn a commission if you click on the link and make a purchase. I only recommend products or services that I personally use and believe will add value to my readers. Your support is appreciated!


The Therapeutic Goods Administration (TGA) has cleared a groundbreaking Ozempic-style pill for Australians to aid with weight loss and treat type 2 diabetes.

The daily GLP-1 pill called Foundayo is expected to be available in just days after the TGA’s ruling on Tuesday.

Foundayo is a small-molecule GLP-1 which targets and simulates a natural hormone in the body to control hunger and slow digestion, the same as popular drugs such as Ozempic and Wegovy.

The Australian arm of US pharmaceutical company Lilly said the drug is a first-of-its-kind GLP-1 pill, which can be taken at any time of the day, without food or water restrictions.

National Association of Clinical Obesity Services President and Associate Professor Samantha Hocking said the clearance could help stem obesity in Australia.

“Australia is grappling with rising rates of overweight and obesity, which now affect around 13 million adults,” Hocking said.

“Obesity is a complex chronic disease that increases the risk of at least 30 other serious medical conditions, ranging from cancer and cardiovascular disease to type 2 diabetes..

“The impact of obesity and type 2 diabetes on individuals, families and our health system highlights the urgent need for stronger prevention efforts and improved access to clinically proven treatment options.”

GLP-1 pill Foundayo has been cleared for Australian use to help combat obesity and type two diabetes.
Camera IconGLP-1 pill Foundayo has been cleared for Australian use to help combat obesity and type two diabetes. Credit: Eli Lilly

The Australian arm of US pharmaceutical company Lilly also celebrated the achievement as the result of more than a decade of research.

“Foundayo clinical trials involved more than 10,000 patients in 15 countries, including partnerships with a dozen Australian hospitals and clinics,” Lilly Australia General Manager Dr Manny Simons said.

“Now that Foundayo can be prescribed, our focus is on ways to deliver broader access for Australians who may benefit from this new medicine.”

The drug is now available through private presciption, but is yet to be added to the Pharmaceutical Benefits Scheme.

Lilly Australia has warned the use of Foundayo with other GLP-1s is “not recommended” and those who take the drug may experience side effects.

It’s the latest Ozempic-style pill to be accepted into the Australian market as more than 13 million adults battle with being overwight or obese.
Camera IconIt’s the latest Ozempic-style pill to be accepted into the Australian market as more than 13 million adults battle with being overwight or obese. Credit: AAP

“The most common side effects affect the digestive system. In clinical trials these effects were mostly mild or moderate in severity and were more frequent during dose escalation, decreasing over time,” the company warns.

“Warnings include low blood sugar when used with insulin or a sulfonylurea and pancreatitis.

“Foundayo should not be used in pregnancy or by people hypersensitive to orforglipron or any ingredient, and some medicines interact with it.”

It’s the latest GLP-1 pill to be approved by the TGA, following Wegovy just weeks prior.



Source link

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *